Skip to main
TEM

TEM Stock Forecast & Price Target

TEM Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 64%
Buy 9%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Tempus AI Inc. has demonstrated robust financial growth, with total revenue increasing by 84.7% year-over-year, primarily fueled by a significant 117.2% rise in genomics revenue, which reached $252.9 million. The company is poised for further revenue enhancement through potential new pharmaceutical contracts and an expected shift towards higher average selling prices (ASPs) for its xF liquid biopsy and xT CDx tests. Additionally, the notable increase in oncology testing volume, with 87.5k NGS tests conducted in Q3 2025, reflects a strong demand for its innovative diagnostic solutions.

Bears say

The key points contributing to a negative outlook on Tempus AI Inc.’s stock are centered around financial performance and risks. The company experienced a decline in gross margins in its Data & Other segment, dropping from 76.8% in Q3 2024 to 69.7% in Q3 2025, signaling potential challenges in maintaining profitability in a competitive market. Additionally, Tempus continues to incur significant losses, has a substantial amount of debt on its balance sheet, and its operating cash flow saw a concerning decrease of $168.5 million year-over-year, raising doubts about its ability to achieve sustainable growth and profitability in the future.

TEM has been analyzed by 11 analysts, with a consensus rating of Buy. 64% of analysts recommend a Strong Buy, 9% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tempus AI Inc (TEM) Forecast

Analysts have given TEM a Buy based on their latest research and market trends.

According to 11 analysts, TEM has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $82.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $82.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tempus AI Inc (TEM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.